Table 1.

Baseline characteristics, renal disease and immunosuppression of PCI group and CABG group [baseline creatinine and GFR displayed for patients without need for haemodialysis only].

	All (n = 51)	PCI (n = 27)	CABG (n = 24)	p-Value
Age, years (IQR)	62 (55–70)	64 (55–73)	62 (54–68)	0.40
Gender male, n (%)	34 (66.7)	21 (77.8)	13 (54.2)	0.14
Baseline creatinine, mg/dl (IQR)	1.7 (1.3–2.1)	1.7 (1.3–2.1)	1.6 (1.3–2.2)	0.91
Glomerular filtration rate, ml/min (IQR)	36.1 (29.8–46.4)	37.4 (31.9–48)	34.5 (25–46.7)	0.51
Chronic haemodialysis, n (%)	11 (21.6)	5 (18.5)	6 (25.0)	0.74
Left ventricular ejection fraction, % (IQR)	60 (50–65)	60 (48.8–65)	55 (50–65)	0.97
Diabetes mellitus, n (%)	15 (29.4)	9 (33.3)	6 (25.0)	0.55
1-Vessel CAD, n (%)	3 (5.9)	0 (0.0)	3 (12.5)	0.10
2-Vessel CAD, n (%)	17 (33.3)	12 (44.4)	5 (20.8)	0.14
3-Vessel CAD, n (%)	31 (60.8)	15 (55.6)	16 (66.7)	0.57
Hypertension, n (%)	51 (100)	27 (100)	24 (100)	>0.99
Peripheral artery disease, n (%)	14 (27.5)	9 (33.3)	5 (20.8)	0.36
Chronic lung disease, n (%)	9 (17.7)	3 (11.1)	6 (25.0)	0.28
Acute indication, n (%)	20 (39.2)	11 (40.7)	9 (37.5)	>0.99
Elective PCI, n (%)	31 (60.8)	16 (59.3)	15 (62.5)	>0.99
Previous PCI, n (%)	31 (60.8)	15 (55.6)	16 (66.7)	0.57
SYNTAX Score I (IQR)	22 (16–29)	20 (13–29)	22 (20−33)	0.19
EuroScore II, % (IQR)	3.3 (1.8–8.9)	2.8 (1.7–5.0)	6.5 (2.0–10.3)	0.10
Renal disease
- Chronic glomerulonephritis, n (%)	24 (47.1)	14 (51.9)	10 (41.6)	0.58
- Diabetic kidney disease, n (%)	2 (3.9)	2 (7.4)	0 (0.0)	0.50
- Polycystic kidney disease, n (%)	8 (15.7)	4 (14.8)	4 (16.7)	>0.99
- Unknown origin, n (%)	10 (19.6)	4 (14.8)	6 (25.0)	0.49
- Other, n (%)	7 (13.7)	3 (11.1)	4 (16.7)	0.69
Immunosuppression
- Cyclosporine, n (%)	11 (21.6)	7 (25.9)	4 (16.7)	0.51
- Tacrolimus, n (%)	20 (39.2)	10 (37.0)	10 (41.7)	0.78
- Mycophenolate mofetil, n (%)	15 (29.4)	6 (22.2)	9 (37.5)	0.36